INFECTIOUS DISEASES GLOBAL CLINICAL TRIAL LANDSCAPE (2025)

2%

OLIGONUCLEOTIDE

THERAPIES

#DYK Did you know?

Biologics:

67% of trials, including

The infectious disease clinical trials market, valued at **\$7B** (2023), will exceed \$13B by 2032 (7% CAGR)


2032

(7% CAGR)

vaccines and monoclonal antibodies **Small Molecules:** 51% 31%, covering SMALL antivirals MOLECULES 67% and antibiotics **BIOLOGICS** Oligonucleotide **Therapies:** 2%, focusing on siR-NA-based treatments **Key Trial Areas, Viral Infections:** COVID-19, HIV/AIDS, Hepatitis B, RSV, Influenza **Other Key Trial Focus Areas:** Pneumonia, mycoses, bacterial (Mycobacterium, Clostridium), and protozoal infections Global Impact: 14M deaths yearly, LMICs hit hardest **Emerging Threats: SARS-CoV-2** variants, monkeypox, Lassa fever NTDs: Schistosomiasis. leishmaniasis, and dengue affect 1B+, underfunded and under-researched AMR Risk: 10M deaths annually by 2050 Innovations: mRNA, gene editing, DCTs drive trials Preparedness: Platform trials, Al, regulatory harmonization boost health security

RAPID GROWTH:

~2,000 industry-led infectious disease trials (2020-2024, ~64% CAGR)



Asia-Pacific (43%), driven by China, Japan, Australia, and India

North America (21%) led by the U.S

Europe (20%) led by UK, Germany, and Spain

ROW (16%) with contributions from South Africa and Brazil



Top Countries: China, U.S, UK



The content of this publication is proprietary to Novotech Health Holdings. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses. Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech. Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights. For permissions or inquiries, please contact: communications@novotech-cro.com